BioSpace News Archive

LB Pharmaceuticals Inc, (“LB”) announced today that results of PET studies of its lead compound to treat schizophrenia, LB-102, have been presented at the European College of Neuropsychopharmacology (ECNP) 2021 conference, held in Lisbon, Portugal.

As previously announced, APTI and the Zeglis lab at the City University of New York, are pursuing a collaboration to investigate APTI’s site-selective conjugation in the rapidly growing field of radioimmunoconjugates (RICs).

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18 years of age and older.

AB Science SA (Euronext - FR0010557264 - AB) today announced that its clinical development program of masitinib in adult patients with mast cell activation syndrome (MCAS) has been approved by the U.S. Food and Drug Administration (FDA).

CCT Research announced today plans to operate as a study site for, and begin enrolling participants into, the global Phase 3 RENOIR (RSV vaccine Efficacy study in older adults Immunized against RSV disease) in the Omaha and Phoenix markets.

Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 13,333,334 shares of the Company’s common stock, at a purchase price of $1.50 per share

With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this one-minute segment Peter recounts how his chest pain dissipated one week after his stem cell treatment, and he recounts how he felt like his life was back to normal after six weeks.

The Barbara Ann Karmanos Cancer Institute and KSP Specialty Pharmacy are pleased to announce the launch of new services and a new website: www.ksppharmacy.org.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to demonstrate the anti-inflammatory activity of XENLETA® (lefamulin).

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced changes to its executive leadership team.